Pharmaceutical

AbbVie’s migraine medication Qulipta gets positive CHMP opinion

The medication could be a strong contender in the EU migraine market as a daily CGRP antagonist for migraines.

Jun 23, 2023 - 20:00
AbbVie’s migraine medication Qulipta gets positive CHMP opinion
The medication could be a strong contender in the EU migraine market as a daily CGRP antagonist for migraines.
Read the original article

Tags:

Previous Article

STAT+: European companies outline opposition to proposed overhaul of pharma policy

Next Article

Intercept winds down NASH programme after FDA pulls plug on Ocaliva

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GLB-001 by GluBio Therapeutics for Refractory Acute Mye...

Dec 20, 2023

STAT+: Senate Republicans throw cold water on so-called site-neutral hospital pay cuts

STAT+: Senate Republicans throw cold water on so-called...

Dec 1, 2023

STAT+: South Africa ordered to disclose contracts with Pfizer, J&J, and other Covid-19 vaccine suppliers

STAT+: South Africa ordered to disclose contracts with ...

Aug 17, 2023